



CANCER CARE AT THE CROSSROADS

 NY - March 31, 2023

A One-Day International Summit on Innovation, Clinical Benefit and Cost

Meet the Sponsors



8:00am - 8:20am

Welcome and Opening Remarks



TOM MANIATIS, PHD

Evin Family Scientific Director and Chief Executive Officer, *New York Genome Center*
Isidore S. Edleman Professor of Biochemistry and Molecular Biophysics, *Columbia University*



MIKE MEYER

Founder,
Meyer Consulting



JOANNE CONROY, MD

President and CEO,
Dartmouth Health

8:20am-9:35am

Round Table 1

Cancer Care through the Lens of Health Plans, Academic Centers, Pharma and Provider Groups



Moderator

JOANNE CONROY, MD

President and CEO,
Dartmouth Health



Panelist

GAIL BOUDREAUX

President and CEO,
Elevance Health



Panelist

SUNEET VARMA

Global Oncology and U.S.
President, *Pfizer*



Panelist

**CLIFFORD A. HUDIS, MD,
FACP, FASCO**

CEO,
*American Society of Clinical
Oncology (ASCO)*



Panelist

TIM BARRY

Co-Founder and CEO,
VillageMD

Round Table 2

9:35am - 10:45am

Round Table 2

The Future of Cancer Science



Moderator

MACE L. ROTHENBERG, MD

Former Chief Medical Officer,
Pfizer



Panelist

JAMES GULLEY, MD, PhD,

Co-Director Center for Immuno-
Oncology, Deputy Director, Center
for Cancer Research, Acting Clinical
Director,
National Cancer Institute



Panelist

**LAWRENCE H. SCHWARTZ,
MD**

Chair, *Department of Radiology,*
Radiologist in Chief,
*Memorial Sloan Kettering Cancer
Center*



Panelist

**ALEXANDER EGGERMONT,
MD, PhD**

CSO, Board of Directors, *Princess
Maxima Center Utrecht*
Professor, Clinical & Translational
Immunotherapy, *UMC Utrecht, Utrecht
University*



Panelist

**APOSTOLIA MARIA
TSIMBERIDOU, MD, PhD,
FASCO, FAAS**

Tenured Professor, Department of
Investigational Cancer Therapeutics,
Division of Cancer Medicine, *The
University of Texas MD Anderson
Cancer Center*

10:45am - 11:00am

Break

Round Table 3

11:00am - 12:15pm

Round Table 3

Improving Patient Outcomes and Addressing Health Disparities in Cancer Care



Moderator

**ADAM MYERS, MD, MHCM,
FACHE**

Chief Clinical Transformation
Officer, *Blue Cross Blue Shield
Association*



Panelist

ELIZABETH FOWLER, PhD, JD

Deputy Administrator and
Director, *Center for Medicare and
Medicaid Innovation*



Panelist

**SELWYN M. VICKERS, MD,
FACS**

President and CEO, *Memorial
Sloan Kettering Cancer
Center*



Panelist

JAMIE REEDY, MD, MPH

Chief Population Health Officer
and Senior Vice President, Health
Solutions, *Horizon Blue Cross Blue
Shield of New Jersey*



Panelist

RUBEN MESA, MD

President, *Enterprise Cancer
Service Line*
Executive Director, *Atrium
Health Wake Forest Baptist
Comprehensive Cancer Center*

1:15pm - 2:30pm

Round Table 4

The Challenges Facing Health Plans, Providers and Governments in Financing Expensive Innovative Cancer Treatment



Moderator

JON ROCKOFF

Health Business Editor and Deputy Coverage Chief for Health and Science, *The Wall Street Journal*



Panelist

GLEN STETTIN, MD

Senior Vice President & Chief Innovation Officer, *Evernorth*



Panelist

KAREN E. KNUDSEN, MBA, PhD

CEO, *American Cancer Society, Inc.* and *American Cancer Society Cancer Action Network*



Panelist

ARIEL DORA STERN, PhD

Associate Professor, *Harvard Business School & Harvard-MIT Center for Regulatory Science*



Panelist

GRACE GRAHAM

Health Policy Director, *U.S. House of Representatives*

Round Table 4

2:30pm - 2:45pm

Break

2:45pm - 4:00pm

Round Table 5

The Future of Personalized Cancer Care



Moderator

RICHARD BARAKAT MD, MBA

Physician-in-Chief and Director, Cancer Services and Research, *Northwell Health Cancer Institute Edward and Carole Miller*
Distinguished Chair in Cancer, SVP, Cancer Services, *Northwell Health*



Panelist

CINDY PERETTIE

Head of Roche Molecular Labs, *Roche Diagnostics* and former CEO, *Foundation Medicine*



Panelist

RICHARD SULLIVAN, MD, PhD

Director, *Institute for Cancer Policy*, Professor of Cancer & Global Health, *King's College*



Panelist

OLIVIER ELEMENTO, PhD

Director, *Englander Institute for Precision Medicine*
Associate Director, Institute for Computational Biomedicine
Associate Program Director, Clinical & Translational Science Center, *Weill Cornell Medicine*



Panelist

ELECTRA D. PASKETT, PhD

Professor and Director, Division of Cancer Prevention and Control, Department of Medicine, College of Medicine, Associate Director for Population Sciences and Community Outreach, Comprehensive Cancer Center, *The Ohio State University*

Round Table 5

Panelist Bios



RICHARD BARAKAT MD, MBA

Physician-in-Chief and Director, Cancer Services and Research, *Northwell Health Cancer Institute Edward and Carole Miller Distinguished Chair in Cancer, SVP, Cancer Services, Northwell Health*

Richard Barakat is an internationally recognized surgeon and clinical investigator who was Chief of the Gynecology Service at Memorial Sloan Kettering from 2001 to 2013 and held the Ronald O. Perelman Chair in Gynecologic Surgery. Dr. Barakat was the lead investigator on several influential clinical trials at MSK, including a study to compare the benefits of laparoscopic versus standard surgery for patients with endometrial cancer and was the lead investigator on an NIH funded national study evaluating symptomatic lower-extremity lymphedema in women undergoing lymphadenectomy for cervical, uterine and vulvar cancer. Dr. Barakat is author or co-author of more than 340 peer-reviewed articles and numerous textbook chapters and was the lead editor of Principles and Practice of Gynecologic Oncology, one of the leading texts in the field.

In addition, he served as a member and examiner for the American Board of Obstetrics and Gynecology and for five years served as a director of the Division of Gynecologic Oncology. He was President of the Society of Gynecologic Oncology from 2013 to 2014 and past President of the International Gynecologic Cancer Society (2014-2016). From 2013 -2017, he served as Director of the MSK regional care network and Cancer Alliance.

In 2018 Dr. Barakat joined Northwell Health to lead all cancer services and research and serve as professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.



TIM BARRY

Co-Founder and Chief Executive Officer
VillageMD

Tim Barry is CEO, Co-Founder, Chair of VillageMD. In this role, Tim evangelizes the vision of a primary care-led healthcare delivery system that brings superior clinical results to the communities where VillageMD works. Through Village Medical, Village Medical at Home, Summit Health, CityMD and other practices, VillageMD serves millions of patients throughout their lives, wherever and whenever they need care. Under Tim's leadership, VillageMD has a dedicated workforce of more than 20,000 operates from 680 practice locations in 26 markets.

Prior to VillageMD, Tim has held numerous senior executive positions across the healthcare spectrum, all focused on empowering healthcare providers to bring value to the market through accountable care and population management. Tim earned degrees from both Cornell University and Michigan State University, and now resides in the Chicagoland area.



GAIL BOUDREAUX

President and Chief Executive Officer
Elevance Health

Gail Boudreaux serves as president and chief executive officer at Elevance Health, where she leads the company in improving lives and communities, simplifying healthcare, and building trust with customers. Her career scaling multi-billion-dollar businesses in the healthcare industry spans over 30 years, including six years as CEO of United Healthcare, a division of UnitedHealth Group, and executive roles at Health Care Service Corporation and Aetna Inc. Today, she oversees Elevance Health's nearly 100,000 associates and 118 million people served, and a growing portfolio of plans and subsidiaries that generated revenue of more than \$137 billion in 2021.

Gail has been named as one of Fortune Magazine's Most Powerful Women in Business... and featured by Forbes as one of 100 Most Powerful Women in the World. Additionally, she has been named by Modern Healthcare as one of the 100 Most Influential People in Healthcare, and she also received the 2018 Billie Jean King Leadership Award and the 2022 NCAA Theodore Roosevelt Award. She earned a bachelor's degree with honors from Dartmouth College and an MBA with distinction from Columbia Business School.

Gail currently serves on the board of directors for Target, the Central Indiana Corporate Partnership, Inc., Blue Cross Blue Shield Association (BCBSA), the Business Council, the National Institute for Health Care Management, American Health Insurance Plans.



JOANNE CONROY, MD

President and Chief Executive Officer
Dartmouth Health

Joanne M. Conroy, MD, has led Dartmouth Health as chief executive officer and president since 2017, overseeing the management of the state's only academic health system and largest private employer in a complex and rapidly evolving healthcare landscape.

Under Conroy's leadership the system's flagship hospital, Dartmouth Hitchcock Medical Center in Lebanon, NH, is regularly ranked as the #1 hospital in New Hampshire by U.S. News & World Report.

Conroy also has moved Dartmouth Health to continue broadening its service to New Hampshire and Vermont communities through partnerships and collaborations in both states. The Dartmouth Health system now includes four hospitals and a home health agency, and a longstanding, strong relationship with the Geisel School of Medicine at Dartmouth continues to provide key academic and research collaborations to train the next generation of physicians.

Conroy has long been a vocal advocate for increasing the role of women in leadership and is often singled out as a role model for other women who aspire to become leaders and agents for positive change in healthcare.

Conroy was named to the American Hospital Association's Board of Trustees in 2019, and in 2022 was named Chair-Elect Designate, to serve as chair of the AHA Board in 2024.

In December, 2022, Conroy was ranked #18 on Modern Healthcare magazine's list of "100 Most Influential People in Healthcare". Other recent national and regional awards and honors of note include being named to Becker's Hospital Review's "Top 113 Great Leaders in Health care" list and the 2021 Citizen of the Year by the New Hampshire Union Leader.

Conroy received her undergraduate degree in chemistry from Dartmouth College and earned her medical degree at the Medical University of South Carolina. She is board certified with the American Board of Anesthesiologists.



ALEXANDER EGGERMONT, MD, PhD

Chief Scientific Officer, Board of Directors, *Princess Maxima Center Utrecht*
Professor, Clinical & Translational Immunotherapy,
UMC Utrecht, Utrecht University

Past Director General of the Gustave Roussy Cancer Institute & Emeritus Full Professor of Oncology (2012-20) (Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Emeritus Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models, drug development.

Scientific Output: is the author or co-author of > 900 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 132; > 90.000 citations (Google Scholar)

International Functions:

Deutsche Krebshilfe: Coordinator German CCC Network Program
European Academy of Cancer Sciences: President, 2010-2020
Cancer Core Europe President – 2014-2020
ECCO: Past President EORTC: Past President
ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board
AACR: Past Deputy Editor of Clinical Cancer Research (2001-2009)
European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:

Legion d'Honneur, France (2015)



OLIVIER ELEMENTO, PhD

Director, *Englander Institute for Precision Medicine*,
Associate Director, *Institute for Computational Biomedicine*
Associate Program Director, *Clinical & Translational Science Center, Weill Cornell Medicine*

Dr. Elemento is a professor of physiology and biophysics at Weill Cornell Medicine (WCM) and Cornell University. Since 2017, he has been the Director of the Caryl and Israel Englander Institute for Precision Medicine. The Englander Institute is a multidisciplinary institute that draws over 100 faculty members from nearly all basic and clinical departments at Cornell University. The Englander Institute's mission is to use genomics, artificial intelligence (AI), patient-derived models and other technologies to develop and bring highly personalized medicine to patients at Weill Cornell's affiliated hospital, New York Presbyterian Hospital (NYPH) and elsewhere. The Institute also fosters patient-centered basic and clinical research in the areas of genomics, systems biology, AI and data science. Dr. Elemento is funded by numerous NIH grants, foundation grants, NIH contracts and industry alliances. He has published over 360 papers in the area of precision medicine, genomics, computational biology, artificial intelligence, systems biology and drug discovery. Dr. Elemento co-founded two venture capital-funded companies, Volastra Therapeutics and OneThree Bio.



ELIZABETH FOWLER, PhD, JD

Deputy Administrator and Director
Center for Medicare and Medicaid Innovation

Dr. Elizabeth Fowler is the Deputy Administrator and Director of the Center for Medicare and Medicaid Innovation at CMS. Dr. Fowler previously served as Executive Vice President of programs at The Commonwealth Fund and Vice President for Global Health Policy at Johnson & Johnson. She was special assistant to President Obama on health care and economic policy at the National Economic Council. From 2008 to 2010, she was Chief Health Counsel to Senate Finance Committee Chair, Senator Max Baucus (D-MT), where she played a critical role developing the Senate version of the Affordable Care Act. She also played a key role drafting the 2003 Medicare Prescription Drug, Improvement and Modernization Act (MMA). Dr. Fowler has over 25 years of experience in health policy and health services research. She earned a bachelor's degree from the University of Pennsylvania, a Ph.D. from the Johns Hopkins Bloomberg School of Public Health, where her research focused on risk adjustment, and a law degree (J.D.) from the University of Minnesota. She is admitted to the bar in Maryland, the District of Columbia, and the U.S. Supreme Court. Dr. Fowler is a Fellow of the inaugural class of the Aspen Health Innovators Fellowship and was elected to the National Academy of Medicine in 2022.



GRACE GRAHAM

Chief Health Counsel
Energy & Commerce Committee, Chair Cathy McMorris Rodgers (WA-05)

Grace Graham is Chief Health Counsel for the Chair of the Energy and Commerce Committee, Cathy McMorris Rodgers (WA-05). She joined the House in February 2021, after almost 10 years on the Senate HELP Committee. She leads the health team for E&C, which includes jurisdiction over Medicaid, FDA, parts of Medicare, NIH, CDC, and many others.

She's worked on major legislative efforts including the No Surprises Act, FDA Safety and Innovation Act, and 21st Century Cures Act.

She received her BS in Biomedical Engineering and Master of Public Policy (MPP) from the University of Virginia.



JAMES L. GULLEY, MD, PHD, FACP

Co-Director, Center for Immuno-Oncology,
Deputy Director, *Center for Cancer Research, NCI*
Acting Clinical Director, *National Cancer Institute*
National Institutes of Health

Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.

Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 200 trials including dozens of first- in-human studies. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a number of vaccines and antibodies including avelumab (Bavencio) and bintrafusp alfa. His clinical studies led to the approval of avelumab in 2017.

Dr. Gulley has authored more than 300 scientific papers and book chapters, edited four books, and has made hundreds of presentations at national and international meetings.



CLIFFORD A. HUDIS, MD, FACP, FASCO

Chief Executive Officer
American Society of Clinical Oncology (ASCO)

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of the Board of ASCO's CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14).

Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through education, research, and support for the delivery of the highest quality of care by the Society's nearly 45,000 members.



KAREN E. KNUDSEN, MBA, PhD

Chief Executive Officer
American Cancer Society, Inc.
American Cancer Society Cancer Action Network

Karen E. Knudsen, MBA, PhD, is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). As a well-respected cancer leader, researcher, and advocate, Dr. Knudsen guides the organization in the goal of improving the lives of cancer patients and their families.

Prior to joining ACS, Dr. Knudsen served as EVP of Oncology Services and enterprise director for Sidney Kimmel Cancer Center—Jefferson Health, one of only 71 National Cancer Institute-designated cancer centers. She also served as president for the Association of American Cancer Institutes (AACI), which is an important voice in advocating for funding for cancer research and access to care, including patient access to research innovations.

Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the nation. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards. She previously served on the board of directors of the American Association for Cancer Research (AACR).



TOM MANIATIS, PhD

Evin Family Scientific Director and Chief Executive Officer
New York Genome Center
Isidore S. Edelman Professor of Biochemistry and

Dr. Maniatis leads the research and operational activities of the New York Genome Center (NYGC), which focus on the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative diseases, and neuropsychiatric diseases. He also directs NYGC's faculty, who lead independent research labs based at the Center. All the core faculty members hold tenure-track joint appointments with one of the Center's member institutions. This arrangement has been a driving force in connecting the NYGC with its founding members.

Dr. Maniatis is recognized as one of the pioneers of modern molecular biology, having led the development of recombinant DNA methods and their application to the study of the mechanisms of gene regulation. He co-authored the definitive laboratory manual on genetic engineering, entitled the *Molecular Cloning Manual*, along with Joe Sambrook and Ed Fritsch in 1982. This three-volume manual, published by the Cold Spring Harbor Laboratory, set a standard for international dissemination of recombinant DNA methods. Dr. Maniatis' research has led to major advances in understanding the mechanisms of gene expression at the level of RNA transcription and splicing. His current research is focused on the role of single cell diversity in neural connectivity, and on the molecular mechanisms that underlie the neurodegenerative disease ALS (Lou Gehrig's Disease).

Dr. Maniatis' research contributions have been acknowledged by membership in the U.S. National Academy of Sciences and the U.S. National Academy of Medicine, and by numerous awards, including the Eli Lilly Research Award in Microbiology and Immunology, the Novartis Drew Award in Biomedical Research, the Richard Lounsbery Award for Biology and Medicine, and the Lasker Koshland Special Achievement Award in Medical Science. He has received honorary PhD degrees from the Cold Spring Harbor Graduate School, the University of Athens, and the Rockefeller University.



RUBEN A. MESA, MD, FACP

President, Enterprise Cancer Service Line, Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Dr. Mesa recently began his tenure at Atrium Health and Atrium Health Wake Forest Baptist as President, Enterprise Cancer Service Line Atrium Health; Enterprise Senior Vice President for Atrium Health; Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; and Vice Dean for cancer programs at Wake Forest School of Medicine. From 2017-2023 Mesa was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successfully renewed the NCI designation in 2020. Mesa practiced hematology at Mayo Clinic (MN 2002-2009, AZ 2009-2017) and was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

Mesa is an international expert in hematologic cancers, who has dedicated his life's work to research and drug development for myeloproliferative neoplasms and led/co-led the development of six drugs that have been FDA approved for myeloproliferative neoplasms and was the inaugural panel chair of the NCCN guideline panel for the first USA guidelines for MPNS. Mesa is passionate about advancing cancer health equity and increasing minority patients' participation in cancer clinical trials, implement a mandate that each new trial at the Mays Cancer Center had a minority accrual plan, and in March 2022, he testified on the importance of clinical trial diversity before the House Committee on Energy and Commerce. Mesa also co-led the Mays Cancer Center's biennial Advancing the Science of Cancer in Latinos Conference held in San Antonio.



ADAM L. MYERS, MD, MHCM, FACHE

Chief Clinical Transformation Officer
Blue Cross Blue Shield Association

Adam L. Myers, MD, MHCM, FACHE is senior vice president and chief clinical transformation officer (CCTO) for the Blue Cross Blue Shield Association (BCBSA), a national federation of 34 independent, community-based and locally operated Blue Cross and Blue Shield (BCBS) companies.

As CCTO, Myers drives clinical transformation across the BCBS System through national networks, health analytics, quality initiatives, and policy and advocacy positions. In his role, he collaborates with the chief medical officers across the 34 BCBS companies and leads the Office of Clinical Affairs (OCA) and the BCBS Institute. Additionally, Myers serves as chief medical officer of the Blues' Federal Employee Program (FEP).

Prior to joining the Association, Myers served as the Cleveland Clinic's chief of population health and director of the Cleveland Clinic Community Care program.

Myers is board-certified in family medicine. He served on the faculty of the University of Oklahoma OB/GYN department and earned the status of Fellow with the American College of Healthcare Executives, The American Institute of Healthcare Quality, and the American Association of Family Physicians.

Myers received his undergraduate degree from Centenary College of Louisiana in Shreveport, and he holds a master's in healthcare management from Harvard University.



ELECTRA D. PASKETT, PhD

Professor and Director, Division of Cancer Prevention and Control, Department of Medicine, College of Medicine, Associate Director for Population Sciences and Community Outreach, Comprehensive Cancer Center, *The Ohio State University*

Electra D. Paskett, Ph.D., became the Marion N. Rowley Professor of Cancer Research at The Ohio State University in 2002. She is the Director of the Division of Cancer Prevention and Control in the College of Medicine, a professor in the Division of Epidemiology, College of Public Health and the Associate Director for Population Sciences and Community Outreach and Co- Program Leader of the Cancer Control Program in the Comprehensive Cancer Center of the Ohio State University (OSU). She is also Founding Director of the Center for Cancer Health Equity at the James Cancer Hospital. She received her doctorate in epidemiology from the University of Washington. Dr. Paskett's almost 400 peer-reviewed publications show-case her work in intervention research directed at cancer prevention, early detection, and survivorship issues. Her studies use multi-level interventions in transdisciplinary teams with community-based participatory research to identify and intervene on factors causing disparities among underserved populations such as social and ethnic minority groups and rural/underserved populations. Dr. Paskett successfully competed for an NCI-funded P50, Center for Population Health and Health Disparities, to examine why rates of cervical cancer are high in Appalachia Ohio and is the Multiple Principal Investigator (MPI) of a large cervical cancer prevention program project in Appalachian regions of four states. She has numerous awards the: American Society of Preventive Oncology Distinguished Achievement Award, Alliance for Clinical Trials in Oncology Jimmie Holland Award, American Association for Cancer Research (AACR) Distinguished Lecture Award on the Science of Cancer Health Disparities, the ASCO-ACS Cancer Prevention Award, and AACR Team Science Award for her long-standing role in the Women's Health Initiative. In 2016, she was appointed by President Obama as a member of the National Cancer Institute's National Cancer Advisory Board, and in 2022 she was re-appointed by Governor Mike DeWine as a member of the Ohio Commission on Minority Health.



CINDY PERETTIE

Head of Roche Molecular Labs, *Roche Diagnostics*
former CEO, *Foundation Medicine*

Cindy Perettie became the Head of Molecular Lab Solutions based in Pleasanton, California on April 6, 2021. Prior to that she was at Foundation Medicine starting in February 2019 as its Chief Executive Officer. Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as senior vice president in global oncology product strategy for Roche's Oncology unit, where she led one of the largest global oncology portfolios in the industry.

Ms. Perettie began her tenure at Genentech as a program team leader for Avastin, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio. Since joining in 2004, she held roles of increasing responsibility at Genentech, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute (SCRI) as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. During her tenure, she was responsible for leading and growing SCRI's contract research organization globally, driving critical oncology clinical trials to further expand options for cancer patients and access precision medicine.

Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation. She started her career as a senior research associate at Johns Hopkins University.



JAMIE REEDY, MD, MPH

Chief Population Health Officer and Senior Vice
President, Health Solutions
Horizon Blue Cross Blue Shield of New Jersey

Dr. Reedy is accountable for provider network management, operations and strategy, clinical transformation and provider engagement, clinical and predictive analytics, medical management (UM, CM, DM), quality management and health equity.

Prior to joining Horizon BCBSNJ in September 2022, Dr. Reedy was the Chief of Population Health for Summit Health, one of the largest physician-led multispecialty groups/physician management companies in the country. Dr. Reedy was responsible for building a comprehensive value-based care model that is considered one of the most successful and innovative of its kind. She previously served as Senior Vice President and Medical Director of Population Health and Quality at Summit Medical Group and Summit Health Management and was also formerly Chief of Hospital Medicine and Post-Acute Care.

Prior to joining Summit in 2011, Dr. Reedy was Medical Director, Compliance Officer and a practicing physician with Paramount Medical Group/Westfield Family Practice in Westfield, NJ. In that role, she led an initiative to become a Level-3 National Committee for Quality Assurance recognized Patient-Centered Medical Home.

Dr. Reedy has a bachelor's degree from NYU and a master's degree in Health Policy and Management from the Johns Hopkins University School of Hygiene and Public Health. She earned her medical degree at the Robert Wood Johnson Medical School. She also completed her internship and a residency in Family Medicine at Robert Wood Johnson. She is board-certified by the American Board of Family Medicine and a Diplomate of the National Board of Medical Examiners.

Dr. Reedy has held board positions with America's Physician Groups, the National Association of ACOs, Paramount Medical Group and the NJ Academy of Family Physicians. She is also a former Chair of the Academy's Government Affairs Committee and a former policy fellow and advisor for the NJ State Senate. Dr. Reedy is a recognized thought leader who has been a featured speaker at many national conferences.



JON ROCKOFF

Health Business Editor and Deputy Coverage Chief
for Health and Science
The Wall Street Journal

Jonathan D. Rockoff is the Health Business Editor at The Wall Street Journal, as well as its Deputy Coverage Chief for Health and Science. Based in New York City, he edits a group of reporters that write about pharmaceutical companies, health insurers and hospitals, while helping oversee science, medicine and public-health reporting. Previously for the newspaper, Jonathan reported on the pharmaceutical and biotechnology industries. He was a member of a team of reporters that was a finalist for the Pulitzer Prize for their coverage of drug pricing. Jonathan has also worked at The Baltimore Sun and The Providence Journal. He is a graduate of Princeton University and the University of Virginia School of Law.



MACE ROTHENBERG, MD

Former Chief Medical Officer
Pfizer, Inc

Mace L. Rothenberg, MD is a physician-executive with more than 30 years of experience in drug development, translational research, and risk-benefit assessment. Dr. Rothenberg served as Chief Medical Officer of Pfizer from 2019 to 2021. Prior to that role, Mace was Pfizer's Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016, and Chief Development Officer for Oncology from 2016 to 2018. During that time, his organization developed and obtained regulatory approval for 11 new cancer medicines including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, Mace was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.

Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society and the Statesman Award from the American Society of Clinical Oncology. He is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Mace is an independent board member and consultant for several biotech companies. He also serves on several advisory and oversight boards at Vanderbilt University, Vanderbilt University Medical Center, and New York University. Mace is Founding Director of a new non-profit endeavor, the Museum of Medicine and Biomedical Discovery.



LAWRENCE H. SCHWARTZ, MD

Chair, Department of Radiology, Radiologist in Chief,
Memorial Sloan Kettering Cancer Center

Lawrence Schwartz, MD, is Chair of the Department of Radiology at Memorial Sloan Kettering. Dr. Schwartz is internationally recognized for his expertise in quantitative imaging, artificial intelligence in cancer imaging, and for his pioneering work in the development and validation of novel imaging biomarkers in oncology. Since 2009, Dr. Schwartz has been Chair of the Department of Radiology at Columbia University Vagelos College of Physicians & Surgeons and Radiologist-in-Chief at NYP/Columbia University Medical Center. Prior to this role, Dr. Schwartz served in a variety of leadership roles at MSK from 1993 to 2009.

Dr. Schwartz is one of the founders of the Quantitative Imaging Biomarkers Alliance of the Radiologic Society of North America and the Quantitative Imaging Network of the National Cancer Institute (NCI). He has multiple NCI grants focusing on imaging biomarker development and validation. Dr. Schwartz also leads multi-institutional projects in imaging biomarker development through open data-sharing in academic/industrial/government partnerships sponsored by the Foundation of the National Institutes of Health and Project DataSphere. He is also involved in translating this work for use in drug discovery and patient care through the National Cancer Trials Network where he chairs the Imaging Committees of Alliance and SWOG.

Dr. Schwartz earned his medical degree at Boston University School of Medicine, his residency at the New York Hospital-Cornell University Medical College, and a fellowship in Cross Sectional Imaging (MRI/US/CT) at Brigham and Women's Hospital and Harvard Medical School. He is a diplomate of the American Board of Radiology and a member of the American Roentgen Ray Society, Radiological Society of North America, International Society for Magnetic Resonance in Medicine, New York Roentgen Ray Society, Society for Computer Applications in Radiology, American Society of Clinical Oncology, and a Fellow at the International Cancer Imaging Society.



ARIEL DORA STERN, PhD

Associate Professor
Harvard Business School & Harvard MIT Center for Regulatory Science

Ariel Dora Stern is Poronui Associate Professor of Business Administration in the Technology and Operations Management Unit at Harvard Business School, where she teaches the MBA course "Transforming Health Care Delivery." Ariel's research focuses on technology management and innovation in health care. Her projects consider the regulation, strategy, and economics of health care, with a focus on understanding the drivers of new product development among firms and the determinants of how new medical technologies are adopted and used in practice. She is a faculty affiliate of Ariadne Labs, a joint center for health systems innovation at Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health and the Harvard-MIT Center for Regulatory Science.

Dr. Stern's research has been cited by Bloomberg, The New York Times, and National Public Radio. She received her Ph.D. from Harvard, where she was a National Bureau of Economic Research Predoctoral Fellow in the Economics of Health and Aging. She holds an undergraduate degree in economics from Dartmouth College, where she was a Presidential Scholar and a two-time U.S. national collegiate figure skating champion. From 2020-2021 Ariel served as the Director for International Health Care Economics at the Health Innovation Hub, the independent think tank of the German Federal Ministry of Health. She is a member of the Scientific Advisory Board of the German Society for Digital Medicine and advises health care start-ups.



GLEN STETTIN, MD

Senior Vice President and Chief Innovation Officer
Evernorth

Dr. Glen Stettin is a champion for new solutions to our clients' and patients' biggest healthcare challenges – affordability, poor care and outcomes, poor experiences and the inequity that amplifies these challenges for members of disadvantaged and marginalized communities. For more than 25 years, Dr. Stettin has been leading innovation, clinical and technical development, and advancing analytic approaches for understanding these big challenges and prompting action on behalf of the clients and patients of the health services businesses that have become Evernorth.

As Chief Innovation Officer, Dr. Stettin applies his expertise in diagnostic and treatment strategies, the behavioral sciences and data science to address the most complex and challenging issues in the coverage and delivery of quality health care. Dr. Stettin's team includes the leaders of the Evernorth Research Institute, which focuses on deeply understanding the big healthcare challenges and approaches to solving them, Evernorth's chief patient and physician experience officers, the heads of our advanced data and analytic capabilities and services, and Evernorth Labs, which brings together more than 200 experts, including physicians, nurses, pharmacists, data scientists and software engineers, across sites in three cities, designed for innovation and collaboration, to focus on solving client and patient pain points, through rapid prototyping, in-house development and partnerships with clients and industry innovators.

Dr. Stettin joined the Cigna Corporation in 2018 through the acquisition of Express Scripts, where he had served as senior vice president & chief innovation officer. He came to Express Scripts in 2012 with the acquisition of Medco, where he served as chief medical officer and, for 17 years, in leadership positions in nearly every corporate function with exception of finance, legal and human resources.

Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, fellow in cardiology and Robert Wood Johnson Clinical Scholar (UCSF/Stanford). He earned his medical and bachelor's degrees through the joint accelerated program of the Medical College of Pennsylvania and Lehigh University.



RICHARD SULLIVAN, MD, PhD

Director, Institute for Cancer Policy,
Professor of Cancer and Global Health
King's College London

Richard Sullivan is Professor of Cancer and Global Health at King's College London and Guy's Comprehensive Cancer Centre. He is director of the Institute of Cancer Policy and Director of the Centre for Conflict & Health Research at King's. He is an NCD advisor to World Health Organization and World Bank. His global cancer research programs cover cancer systems strengthening, financing, political economy, global cancer surgery particularly virtual reality-enhanced surgical simulation training, as well as studies into social welfare and cancer care in conflict. He also directs a number of major research programs in conflict and health with a special focus on the Middle East, including Health Security Intelligence, Global Health Security and health systems strengthening in conflict. Professor Sullivan trained in surgery (urology) gaining his PhD in Biochemistry from University College London. Richard was formerly Clinical Director of Cancer Research UK for nearly ten years and is a surgeon by background.



APOSTOLIA MARIA TSIMBERIDOU, MD, PhD, FASCO, FAAAS

Tenured Professor, Department of Investigational
Cancer Therapeutics, Division of Cancer Medicine
The University of Texas, MD Anderson Cancer Center

Apostolia M. Tsimberidou, MD, PhD is a Professor of Medicine in the Department of Investigational Cancer Therapeutics at The University of Texas, MD Anderson Cancer Center. Dr. Tsimberidou has designed highly innovative clinical trials that have changed the standard of practice of oncology and improved the clinical outcomes of patients with solid tumors and hematologic malignancies. She pioneered the personalized medicine program across tumor types at M.D. Anderson. In 2007, she developed the IMPACT (Initiative for Personalized Medicine and Advanced Cancer Therapy) program and demonstrated that identifying tumor specific molecular aberrations and selecting therapy based on tumor abnormalities of individual patients with advanced cancer is associated with better overall outcomes compared with standard approaches. Her research accomplishments have garnered extensive media coverage by ASCO, The Economist, the Wall Street Journal, the Bloomberg report and the Boston Globe. She has published >315 articles in high-impact peer-reviewed journals and book chapters and co-edited major textbooks in Oncology. She has been invited to present her work at numerous conferences. She has received prestigious awards and she was appointed to serve on several committees at ASCO and the Worldwide Innovative Network (WIN) consortium in Precision Medicine. She is a board member of the Coalition for Personalized Medicine. Dr Tsimberidou is a Fellow of ASCO (FASCO) and a Fellow of the American Association for the Advancement of Science (AAAS) for "seminal contributions to instantiating and implementing precision oncology through innovative therapeutic approaches, patient care, and education aimed at improving clinical outcomes across tumor types".



SUNEET VARMA

Global Oncology and U.S. President
Pfizer

Suneet Varma is Global and U.S. President, Oncology, which is committed to advancing medicines wherever we believe we can make a meaningful difference for people living with cancer. Pfizer has an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications and is focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Before joining Oncology, Suneet served as Global President, Rare Disease, one of Pfizer's fastest-growing, high science business units which includes gene therapy and aspires to pioneer breakthroughs that have a profound impact on the lives of underserved patient populations. Prior to that, Suneet served as Global President, Hospital, one of Pfizer's largest business units covering Anti-Infectives, Blood Management and Pain & Anesthesia (among others). Additional prior roles included serving as Global President, Essential Health group and President and General Manager of Pfizer Consumer Healthcare.

Notably, Suneet was awarded as one of the 2019 Outstanding 50 Asian Americans in Business by the Asian American Business Development Center. He currently sits on The Board of Trustees of Drew University, the Board of Trustees of Kent Place School and the Board of Directors for Cerevel Therapeutics, a company dedicated to treating neuroscience diseases. He also represents Pfizer on the Healthcare Leadership Council. Suneet has chaired or been a part of many other several industry associations over his career. He has also been featured in various publications and has spoken at several panels, universities, and conferences.

Suneet received his MBA from the Harvard Business School and a BS in Engineering from Tufts University.



SELWYN M. VICKERS, MD, FACS

President and Chief Executive Officer
Memorial Sloan Kettering Cancer Center

Selwyn M. Vickers is the President and CEO of Memorial Sloan Kettering Cancer Center. He assumed the role on September 19, 2022.

Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Vickers is the immediate past president of the American Surgical Association. Vickers continues to see patients.

In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and chair of the Department of Surgery at the University of Minnesota Medical School.

While at Minnesota, the lab of Vickers and Ashok Saluja, Ph.D., was instrumental in the development of an injectable cancer drug, Minnelide, which is licensed and entered phase II trials for the treatment of pancreatic and gastrointestinal cancer in 2019. He is a patent holder and has a limited financial interest in Minneamrita Therapeutics, LLC, the pharmaceutical company licensed to develop the drug.

In 2013, Vickers became senior vice president of Medicine and dean of the UAB Marnix E. Heersink School of Medicine, one of the largest public academic medical centers in the United States. In his role as dean, Vickers led the medical school's main campus in Birmingham as well as its regional campuses in Montgomery, Huntsville, and Tuscaloosa.

On January 1, 2022, Vickers assumed the roles of CEO of the UAB Health System and CEO of the UAB/Ascension St. Vincent's Alliance, while retaining his role as dean of the UAB Heersink School of Medicine.

Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two post-graduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children.



MIKE MEYER

Founder and President
Meyer Consulting

Mike Meyer is an entrepreneur, author, health care expert, and founder and host of the CCX Cancer Summit held each year in New York City. He is the President of Meyer Consulting. Early in the pandemic, he coauthored an op-ed in the Wall Street Journal titled Medical Lockdown will Cause a Disease Surge, which proved remarkably accurate. He is known for his work with leading health systems, academic medical centers and health care companies. Over the years, he has built or helped grow multiple health care companies.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing executive search, strategic consulting, and human capital consulting. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Blue Cross Blue Shield Association, Horizon Blue Cross Blue Shield NJ, Pfizer, MD Anderson Cancer Center, Summit Medical Group, California Association of Health Plans, WIN Consortium for Personalized Cancer Medicine and numerous other academic centers, large providers, physician groups and other not-for-profit health care organizations.

Meyer's early career was as vice president in charge of the New York office of Amherst Associates, which went public in 1981. He subsequently became a senior partner in Witt Kieffer before founding Meyer Consulting in 2007. Meyer founded Cancer Care at the Crossroads (CCX) Summit in 2016. This one-of-a-kind event brings together senior health care executives from the US and international. In 2019 Meyer Consulting's executive search practice was acquired by Westwood & Wilshire, one of the premier firms in life sciences and technology.

Meyer was a board member of Summit Select, part of Summit Medical Group which merged with CityMD, creating one of the largest private physician groups in the U.S., with support from Warburg Pincus. He cofounded the Institute for Mental Health Research (www.imhr.org) and is a board member of the Human Health and Research Foundation (<http://hherf.org>). He has been widely quoted on healthcare, oncology, mental health and retiree topics in healthcare and business publications. He is the author of Catastrophic Illness and Catastrophic Health Insurance published by the Heritage Foundation, and coauthor of Destination Southwest, a Guide to Retiring and Wintering in Arizona.

Meyer Consulting is an international health care consulting and recruiting firm that brings leading experts together in collaborative settings to build better health care solutions.





MEYER CONSULTING

Phone (406) 531.5505

Fax (480) 614.5660

Website www.meyerconsultinginc.com

CORPORATE OFFICE

MEYER CONSULTING, LLC

5665 N Scottsdale Rd, Suite 110

Scottsdale, AZ 85250